Bellerophon Therapeutics, Inc. (BLPH)
Stock Price:
$12.15 USD
0.07 (0.58%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $11.76 -0.39 (-3.21%) Aug 7, 6:41 PM
Key Info
| Market Cap |
115.40M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.16M |
| Shares Out |
9.50M |
| EPS (ttm) |
-3.22 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$12.15 |
| Previous Close |
$12.08 |
| Change ($) |
0.07 |
| Change (%) |
0.58% |
| Day's Open |
12.01 |
| Day's Range |
11.76 - 12.22 |
| Day's Volume |
89,736 |
| 52-Week Range |
3.19 - 26.00 |
More Stats
| Market Cap |
115.40M |
| Enterprise Value |
57.98M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
9.50M |
| Float |
6.57M |
| EPS (basic) |
-3.34 |
| EPS (diluted) |
-3.22 |
| FCF / Share |
-2.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
476,615 |
| Short Ratio |
1.70 |
| Short % of Float |
5.17% |
| Beta |
-0.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
53.46 |
| Revenue |
n/a |
| Operating Income |
-18.78M |
| Net Income |
-17.16M |
| Free Cash Flow |
-15.42M |
| Net Cash |
57.42M |
| Net Cash / Share |
6.05 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-28.20% |
| ROE |
-52.90% |
| ROIC |
1,274.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$31.67*
(160.66% upside)
Low
30.0
Current: $12.15
High
35.0
Target: 31.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -17.47 | -27.88 | -24.60 | -23.76 | -46.57 | -59.75 | -62.00 | -46.23 |
| Net Income | -13.27 | 2.81 | -54.82 | -23.81 | -46.46 | -59.67 | -62.00 | -46.23 |
| Shares Outstanding | 4.50 | 3.83 | 2.60 | 1.00 | 0.82 | 0.53 | - | - |
| Earnings Per Share | -2.95 | -5.07 | -21.11 | -23.70 | -56.85 | -113.39 | - | - |
| Operating Cash Flow | -12.94 | -15.50 | -15.90 | -17.21 | -46.26 | -70.56 | -57.23 | -36.22 |
| Capital Expenditures | - | - | - | -0.02 | -0.46 | - | -0.73 | -3.48 |
| Free Cash Flow | -12.94 | -15.50 | -15.90 | -17.24 | -46.72 | -70.56 | -57.96 | -39.70 |
| Cash & Equivalents | 9.98 | 16.75 | 32.22 | 20.17 | 24.07 | 26.08 | 0.00 | 0.00 |
| Total Debt | 2.32 | - | - | - | - | - | - | - |
| Net Cash / Debt | 7.66 | 16.75 | 32.22 | 20.17 | 24.07 | 26.08 | 0.00 | 0.00 |
| Assets | 13.11 | 18.36 | 36.81 | 29.70 | 38.41 | 33.39 | 3.64 | - |
| Liabilities | 9.52 | 14.50 | 39.40 | 11.71 | 8.07 | 10.45 | 19.37 | - |
| Book Value | 3.59 | 3.86 | -2.59 | 17.99 | 30.34 | 22.94 | -15.74 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Bellerophon Therapeutics, Inc. |
| Country |
United States |
| Employees |
18 |
| CEO |
Fabian Tenenbaum |
Stock Information
| Ticker Symbol |
BLPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BLPH |
| IPO Date |
February 13, 2015 |
Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.